滚动资讯
FierceBiotechRyghtAI launches clinical site search engine to aid drug developers, CROs with trial designBioWorldSex differences shape gene activity across the human brainFierceBiotechRare Disease Research, myTomorrows team up to help patients access trialsFierceBiotechAligos sells China rights to HBV drug to hepatology player Amoytop in $445M dealFierceBiotechPfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trialFierceBiotechJohnson & Johnson hands back failed eye disease gene therapy to MeiraGTxFierceBiotech'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once againBioWorldFDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADCBioWorldMeta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’BioWorldMeta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’Thermo FisherThermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy? - Yahoo FinancePLoS BiologyGlucose is dynamically regulated by time of day in humans and <i>Drosophila</i>
FierceBiotech 2026年4月16日

Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

原文
暂时没有全文，请查看原始来源。